ArticleJournal of the American Heart Association2024
Revealing the Novel Role of Purinergic Receptor P2X4 in Phagocytic Uptake After Ischemic Stroke.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Microglia and neuroinflammation: function, heterogeneity, and crosstalk.Cellular & molecular immunology · 2026Review
- P2X4 purinergic receptor loss alters macrophage homeostasis, cytokine secretion, and phagocytosis in a myeloid-specific P2X4 purinergic receptor knockout mouse.Frontiers in immunology · 2026Article
- Inflammation-centered neurovascular-immune-metabolic remodeling in ischemic stroke: stage-dependent mechanisms, regulated cell death, and therapeutic translation.Frontiers in immunology · 2026Review
- Cellular Communication Networks Mediated by Microglia in Ischemic Stroke.CNS neuroscience & therapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPurinergic receptor P2X4 (P2X4R), highly expressed on microglia and macrophages, is activated by ATP released from damaged cells and linked to poststroke inflammation. Previous studies showed that short-term P2X4R inhibition reduces inflammation and promotes long term recovery, but the mechanism underlying P2X4R and inflammation remains unclear. We hypothesized that P2X4R absence or pharmacological blockade can enhance macrophage phagocytic function by alleviating excessive inflammation after stroke. METHODS AND
resultsWe divided P2X4R knockout and littermate control mice into 2 groups either naive or mice subjected to ischemic stroke surgery. Additionally, the regular WT mice subjected to ischemic stroke were treated with 5-(3-Bromophenyl)-1,3-dihydro-2H-Benzofuro[3,2-e]-1,4-diazepin-2-one BD (a P2X4R inhibitor) or vehicle. We isolated phagocytic cells from mice in each group and assayed phagocytic activity by quantifying uptake of fluorescent beads and bioparticles using flow cytometry or confocal microscopy and by measuring protein expression related to phagocytosis. Short-term inhibition of P2X4R with with 5-(3-Bromophenyl)-1,3-dihydro-2H-Benzofuro[3,2-e]-1,4-diazepin-2-one treatment upregulated ANXA1 (annexinA1). P2X4R absence prevented ATP-induced decline in phagocytic uptake in macrophages. Microglia or macrophages derived from P2X4R knockout mice showed significantly increased phagocytic activity compared with microglia/macrophages taken from littermate control mice. Cell surface expression of CD36, a scavenger receptor protein, increased after stroke, and was higher in P2X4R knockout mice.
conclusionsThis study suggests that blockade or absence of P2X4R increases phagocytic uptake of damaged tissue following ischemic stroke. Taken together with previous reports detailing how P2X4R inhibition is protective following stroke, our results demonstrate P2X4R may mediate long-term resolution after ischemic stroke by enhancing phagocytic clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.